Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the relative risk of kidney failure, 50% decline in eGFR, or death by 24%.[1][1] A meta-analysis of 64 286
Authors
- Irfan Khan (ORCID: https://orcid.org/0009-0000-0014-1194)
- Matthew B. Lanktree (ORCID: https://orcid.org/0000-0002-5750-6286)
Institutions
- University College Cork (IE)
- McMaster University (CA)
Publication Details
- Journal
- Canadian Medical Association Journal
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1503/cmaj.240469
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00